RICT 2016

Online registration is still open! REGISTER NOW!

Media Partner

Conferences > Archives > RICT 2016 > Editorial

Editorial 2016

This year’s International Conference on Medicinal Chemistry marks a turning point for chemical biology. New convergences point towards an accelerated path to the discovery of new medicines.

The means by which new drugs are discovered has irreversibly changed, moving from empirical approaches to the emerging chemical biology discipline, which also includes computational and robotic approaches. An interdisciplinary strategy involving chemistry, life sciences and physics has always been the key to hacking major biomedical problems and to provide solutions to drug discovery. New convergences point towards an accelerated path to the discovery of new medicines. The changes in our laboratories are already visible as we have introduced new technologies and new competences among collaborators.

So it is great news that an increasing level of dialogue between chemists, biologists, medicinal chemists, pharmacologists, and physicians has emerged in recent years, with the completion of the Human Genome Project, a milestone in this productive integration of how to think about achieving these objectives. And all of this comes at the same time as technology has transformed our laboratories. We have to think of progress in high-throughput screening initiatives, DNA microarrays, proteomics, protein microarrays, computational inference methods, availability of large collections of diverse datasets, and could go on.

The two main aspects of modern drug discovery are directed towards identification of new targets, and discovery and development of active small molecules against them.  Identification of new targets is a crucial process. It can be approached by direct biochemical techniques, genetic interactions or computational inference. Identification and development of new active molecules, using target-based approaches associated with molecular and cellular bioassays for the newly identified targets, then becomes the crucial step in the drug discovery process.

The objective is then to investigate the basic questions in biology, and one aspect is to study interactions between small molecules and proteins to open new avenues for future drug discovery. Nowadays, chemical biology has become widely accepted to discover drug leads and represents the prevailing path of therapeutic innovation in which identification and validation of novel targets of drug action are of major concern.

An example among others of the new direction of drug discovery integrating chemical biology includes the field of peptides. They are important natural compounds possessing diverse and interesting biological and physiological functions. However, this far, they only attracted scant attention from pharmaceutical companies. Perhaps they need to think again. The directed evolution techniques, the potential of peptides in modulating protein-protein interactions, and the progress in technologies to deliver peptides, makes this class of compounds among the most interesting on the block.   
None of this makes our task necessarily easier. All these techniques and technologies have to be integrated in a combination of methodologies to fully characterise on-target and off-target effects of a therapeutic molecule, to better understand disease and discover new drugs.

Further complicating this are the connections in this new world between the public sector with its strong role in fundamental and basic research including target discovery and technology improvements, and the private sector, which is able to perform target validation and drug development. They have to be strengthened.
Now the question is whether we can deliver the goods.

It is worth getting this as optimal as possible because there is an urgent necessity to develop new therapeutic agents using the most advanced technologies, to treat under-served common pathologies including bacterial infections and metabolic disorders, as well as diseases associated with ageing (e.g. neurological diseases).

Interfacing Chemical Biology and Drug Discovery is the topic chosen by the organisers of the RICT 2016. At this conference we will learn more about the convergence of developments in medicinal chemistry, robotics and computation that could indeed be about to spark a revolution in the discovery of new medicines. Through the program that has been set up, leading researchers from academia and industry will present important topics in the area of chemical biology, and for sure will stimulate discussions and result in sharing information and the further collaborations that will help all of us to make a contribution to drug discovery.

Jean Martinez
Professor of Medicinal Chemistry
University of Montpellier
IBMM, UMR 5247

Printable version of the editorial (03/05/2016 - 80 KB)


Organised by

EFMC Sponsored Event

Premium Exhibitor

Sponsors

Media Partners

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys